Peter Anevski; Chief Executive Officer, Director; Progyny Inc. Mark Livingston; Chief Financial Officer; Progyny Inc. Michael Sturmer; President; Progyny ...

Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). A landmark deal ...

Today, Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to ...